HC Wainwright Reiterates Buy Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

HC Wainwright reiterated their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a report published on Thursday,Benzinga reports. HC Wainwright currently has a $19.00 price target on the stock.

Several other research analysts have also recently issued reports on the stock. Ascendiant Capital Markets increased their price objective on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a report on Monday, December 2nd. D. Boral Capital reiterated a “buy” rating and issued a $31.00 price objective on shares of NRx Pharmaceuticals in a report on Monday.

NRx Pharmaceuticals Trading Down 5.0 %

Shares of NASDAQ:NRXP opened at $2.07 on Thursday. The firm’s 50 day moving average is $2.88 and its two-hundred day moving average is $2.03. NRx Pharmaceuticals has a 52 week low of $1.10 and a 52 week high of $6.01. The firm has a market capitalization of $35.02 million, a P/E ratio of -0.97 and a beta of 1.22.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings data on Friday, March 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.10). Analysts predict that NRx Pharmaceuticals will post -1.75 EPS for the current year.

Institutional Trading of NRx Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Townsquare Capital LLC bought a new stake in NRx Pharmaceuticals during the third quarter worth approximately $25,000. Sassicaia Capital Advisers LLC bought a new stake in NRx Pharmaceuticals during the fourth quarter worth approximately $33,000. Squarepoint Ops LLC bought a new stake in NRx Pharmaceuticals during the fourth quarter worth approximately $56,000. Millennium Management LLC purchased a new stake in shares of NRx Pharmaceuticals in the 4th quarter valued at approximately $61,000. Finally, Anson Funds Management LP purchased a new stake in shares of NRx Pharmaceuticals in the 3rd quarter valued at approximately $241,000. 4.27% of the stock is currently owned by institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.